Join the 'Positron Emission Tomography Imaging' group to help and get support from people like you.
Positron Emission Tomography Imaging News
Related terms: PET Imaging
Posted 16 Jun 2016 by Drugs.com
June 1, 2016 – The U.S. Food and Drug Administration today approved Netspot, the first kit for the preparation of gallium Ga 68 dotatate injection, a radioactive diagnostic agent for positron emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with the rare condition, somatostatin receptor positive neuroendocrine tumors (NETs). NETs ...
FDA Approves Axumin (fluciclovine F 18) Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
Posted 1 Jun 2016 by Drugs.com
May 27, 2016 – The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment. Prostate cancer is the second leading cause of death from cancer in U.S. ...
Posted 20 Mar 2014 by Drugs.com
Berlin/Boston, March 20, 2014‒ Piramal Imaging today announced that the U.S. Food and Drug Administration (FDA) has approved Neuraceq. This approval comes only four weeks after receiving marketing authorization for Neuraceq from the European Commission. Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult p ...
Posted 11 Nov 2013 by Drugs.com
FRIDAY, Oct. 25 – Vizamyl (flutemetamol F 18 injection) has been approved by the U.S. Food and Drug Administration for use with positron emission tomography (PET) imaging of the brain to screen adults for signs of Alzheimer's disease and other forms of dementia. Dementia – characterized by deteriorating memory, judgment, language and motor skills – has been associated with brain accumulation ...
Posted 12 Sep 2012 by Drugs.com
WEDNESDAY, Sept. 12 – Choline C 11, an imaging agent used for positron emission tomography (PET) testing, has been approved to help detect recurring prostate cancer, the U.S. Food and Drug Administration said Wednesday in a news release. The injected substance helps produce an image that allows doctors to identify tissues to test for the disease, the agency said. It warned that PET testing was ...
Ask a Question
Related Condition Support Groups
Related Drug Support Groups
rubidium chloride rb-82, florbetapir f 18, flutemetamol f 18, florbetaben f-18, fluciclovine f 18, gallium ga 68 dotatate, choline c-11, Cardiogen-82, Amyvid, Vizamyl, Neuraceq, Axumin, Netspot, Ruby-Fill